Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan

UMMS Affiliation

Department of Pediatrics

Publication Date


Document Type



Confidence Intervals; Dihydroxyphenylalanine; Female; Humans; Infant; Infant, Newborn; Injections, Intravenous; Male; Pancreas; Persistent Hyperinsulinemia Hypoglycemia of; Infancy; Positron-Emission Tomography; Prospective Studies; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index


Endocrinology, Diabetes, and Metabolism | Pediatrics


OBJECTIVES: To assess the accuracy of 18F-fluoro-L-dihydroxyphenylalanine ([18F]-DOPA) PET scans to diagnose focal versus diffuse disease and to localize focal lesions in infants with congenital hyperinsulinism.

STUDY DESIGN: Twenty-four infants with hyperinsulinism unresponsive to medical therapy were studied. Patients were injected intravenously with [18F]-DOPA, and PET scans were obtained for 1 hour. Images were coregistered with abdominal CT scans.

RESULTS: The diagnosis of focal or diffuse hyperinsulinism was correct in 23 of the 24 cases (96%) and equivocal in 1 case. [18F]-DOPA PET identified focal areas of high uptake of radiopharmaceutical in 11 patients. Pathology results confirmed that all 11 had focal adenomatosis, and the locations of these lesions matched the areas of increased [18F]-DOPA uptake on the PET scans in all of the cases.

CONCLUSIONS: [18F]-DOPA PET scans were 96% accurate in diagnosing focal or diffuse disease and 100% accurate in localizing the focal lesion. These results suggest that [18F]-DOPA PET imaging should be considered in all infants with congenital hyperinsulinism who need to have pancreatectomy.

DOI of Published Version



J Pediatr. 2007 Feb;150(2):140-5. Link to article on publisher's site

Journal/Book/Conference Title

The Journal of pediatrics


At the time of publication, Olga Hardy was not yet affiliated with the University of Massachusetts Medical School.

Related Resources

Link to Article in PubMed

PubMed ID